BioNTech SE and Pfizer Inc's COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm's chief executive officer.
FILE PHOTO: A small bottle labeled with a"Vaccine" sticker is held near a medical syringe in front of displayed"Coronavirus COVID-19" words in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo
- BioNTech SE and Pfizer Inc’s COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm’s chief executive officer. The experimental vaccine, which showed promise against the fast-spreading respiratory illness in early stage human testing, is expected to move into a large trial involving 30,000 healthy participants later this month, pending regulatory nod.
If it receives marketing approval, the companies are preparing to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States, Reuters reported last week. Several hundred million doses could be produced even before the approval, according to the WSJ reportReporting by Manojna Maddipatla in Bengaluru
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Could a coronavirus vaccine rehab the pharmaceutical industry's reputation despite drug price increases?For years, the pharmaceutical industry has faced withering bipartisan criticism and a deteriorating reputation among the public for its role in driving up drug prices.
Read more »
As Vaccine Skepticism In U.S. Grows, Experts Recommend Strategies For Covid-19 Vaccination CampaignPolling suggests only 50% of the population would get a Covid-19 vaccine were it available.
Read more »
Potential COVID-19 vaccine not 'single solution' to pandemic, Johnson & Johnson CEO saysU.S. drugmaker Johnson & Johnson aims to begin clinical testing of its COVID-19 vaccine in the coming weeks and produce billions of doses in 2021, chief executive officer Alex Gorsky said on Wednesday, but cautioned that it will take more than one vaccine to rein in the virus.
Read more »
Covid-19 Vaccine Trials Now Open To Volunteers In U.S.The National Institute of Allergy and Infectious Diseases launched the website Covid-19 Prevention Network on Wednesday, merging four existing clinical trial networks and setting up an operation across over 100 different sites in the United States and internationally.
Read more »
Here’s how small businesses threatened by COVID-19 are surviving the pandemicSalons, restaurants, florists and fitness instructors, among others, are creatively adjusting to the new realities of the coronavirus economy, pivoting to bringing parts of their business online.
Read more »
Perspective | The deadly fallout of disinformationHow the history of Soviet disinformation after Chernobyl sheds light on our fight against covid-19.
Read more »